US › Healthcare

Orchestra BioMed Holdings Inc. (OBIO)

US · Healthcare · Biotechnology

$4.27+3.64%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$110,000
Revenue YoY
-87.3%
Net profit
$-20.7M
Profit YoY
-10.3%
EPS
$-0.33
EPS estimate
$-0.44
Net margin
-18,810.0%

EPS came in at -0.33 against a street estimate of -0.44 — a beat of 25.5%.

Key statistics

Market cap
$238.3M
Forward P/E
0.0
P/B
5.79
Book value
$0.70
EPS (TTM)
$-0.95
52-week high
$5.42
52-week low
$2.20
50-day MA
$3.95
200-day MA
$4.15
Beta
0.48

Analyst view

Analysts rate Orchestra BioMed Holdings Inc. a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $12.17.

Shareholding

Insiders
24.57%
Institutions
42.28%

Largest institutional holders

FundStake
RTW INVESTMENTS, LLC13.87%
Perceptive Advisors LLC8.41%
Vanguard Capital Management, LLC3.68%
Vanguard Group Inc2.68%
Alyeska Investment Group, L.P.1.67%
Propel Bio Management LLC1.50%
Millennium Management LLC1.17%
BlackRock Inc1.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Orchestra BioMed Holdings Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.